BioCryst Licenses Navenibart in Europe, De-Risking Pipeline but Leverage Remains Heavy

What happened

BioCryst granted an Irish affiliate of Neopharmed Gentili exclusive European rights to commercialize navenibart for hereditary angioedema, providing non-dilutive validation for the long-acting injectable acquired via the Astria deal. The financial terms are undisclosed, and the European contribution is likely modest relative to the U.S., but the deal signals commercial interest in the pipeline asset. This news incrementally de-risks the navenibart binary, though the core dependency on Orladeyo's growth to service ~$736M net debt remains unchanged. The stock still trades at a rich EV/EBITDA multiple, and interest coverage of 0.85x leaves little room for error.

Implication

The European license validates navenibart's market potential and could serve as a template for other regions, supporting the dual-modality HAE thesis. Combined with Orladeyo's growth and pediatric expansion, risk/reward improves if management sustains margin expansion and delivers debt reduction over 12-18 months.

Thesis delta

The European license adds a small positive catalyst by validating navenibart and providing non-dilutive cash, but does not materially alter the fundamental risk profile; the thesis still hinges on Orladeyo compounding toward ~$1B peak sales while managing leverage, and the WAIT rating remains appropriate.